Evidence map›Paper›PMID 33077630›Full record

ReviewJournal of bacteriology2021

Gut Microbiota: the Emerging Link to Lung Homeostasis and Disease.

An Zhou, Yuanyuan Lei, Li Tang, Shiping Hu, Min Yang, Lingyi Wu, Shiming Yang, Bo Tang

Open access · greenAbstract readReview
In one paragraph

Review in Journal of bacteriology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

An Zhou *Department of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Yuanyuan Lei *Department of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Li TangDepartment of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Shiping HuDepartment of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Min YangDepartment of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Lingyi WuDepartment of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China.
Shiming YangDepartment of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China Yangshiming@tmmu.edu.cn botangxq@tmmu.edu.cn.
Bo TangDepartment of Gastroenterology, Xinqiao Hospital, Army Medical University, Chongqing, China Yangshiming@tmmu.edu.cn botangxq@tmmu.edu.cn.ORCID 0000-0003-3967-1576
Army Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota plays a crucial role in the development of the immune system and confers benefits or disease susceptibility to the host. Emerging studies have indicated the gut microbiota could affect pulmonary health and disease through cross talk between the gut microbiota and the lungs. Gut microbiota dysbiosis could lead to acute or chronic lung disease, such as asthma, tuberculosis, and lung cancer. In addition, the composition of the gut microbiota may be associated with different lung diseases, the prevalence of which also varies by age. Modulation of the gut microbiota through short-chain fatty acids, probiotics, and micronutrients may present potential therapeutic strategies to protect against lung diseases. In this review, we will provide an overview of the cross-talk between the gut microbiota and the lungs, as well as elucidate the underlying pathogenesis and/or potential therapeutic strategies of some lung diseases from the point of view of the gut microbiota.

Indexed as

AnimalsDysbiosisGastrointestinal MicrobiomeHomeostasisHumansLungLung Diseasesgut microbiotaimmunitylunglung diseasemicrobiome

Identifiers

PMID33077630
PMCPMC7847545
OpenAlexW3093227104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.